Coronis is a leading Israeli Investment Company specializing in the Biotechnology sector and focusing on highly select opportunities in the therapeutic, diagnostic and agro-bio space. Coronis' team, comprised of industry experts with complementary expertise from operational, finance, and management backgrounds, has invested since 2004 over $10M in seven high quality portfolio companies. As of August 2009, Coronis' portfolio valuation has doubled , representing an IRR of more than 30% per year.
Study of hGH-CTP Given Once-Weekly to Growth Hormone Deficient Adults for Four Months Reaffirms Prior Phase II Findings Showing a Single Weekly Injection of hGH-CTP has Potential to Replace Seven Daily Injections of Commercial hGH
MOD-6030 Administered Once Weekly Over 30 Days Produced 28% Weight Loss and Improved Glycemic Profiles.
Other Potential Health Benefits Included 57% Reduction in Cholesterol Levels.
Data to Be Presented at 5th Diabetes Drug Discovery and Development Conference.
Over 200,000 SNPs identified in wheat genome as part of effort to improve wheat traits through advanced breeding
PROLOR BIOTECH ANNOUNCES POSITIVE PRECLINICAL RESULTS FROM COMPARATIVE STUDY OF ITS LONG-ACTING CLOTTING FACTOR VIIa
Factor VIIa-CTP May Provide Hemophilia Patients Prolonged Protection
from Bleeding. PROLOR Now Has Two Promising Long-Acting Coagulation Factors with the Potential to Address Important Unmet Medical Needs.
PROLOR has received a notice of allowance from the U.S. - PTO for a patent application covering the company’s CTP platform, which has the potential to extend the duration of activity of virtually all therapeutic proteins.